2D·

My portfolio update August 2025: Strength despite tech weakness & tactical realignment 📊🗓️

Hello Community,

August is over and it's time for the transparent monthly review. The portfolio has reached a new high of € 36,188. It was a month of contrasts, in which the strength of some satellites offset the weakness in the tech sector.

1. the performance: 🚀

Beating the market 📈

With a monthly performance of +0,94% I am very satisfied. As the chart shows, my portfolio clearly outperformed the broad market (FTSE All-World: -0.31%) and the major US indices (S&P 500: -1.11%, NASDAQ100: -2.23%). The result proves the strength of diversification: while my tech stocks corrected, other sectors carried the performance.

2. my buys & sells: 🛒

None ❌

In August, I deliberately kept my feet still and did not make any individual purchases or sales. My focus was on waiting for the important quarterly reports and preparing my tactical purchases for September.

3. my savings plans & purchases in September: Tactical allocation 💸

As you know, I take a flexible approach to my individual shares and adjust my purchases on a monthly basis. Only my ETF savings plans run consistently. My allocation for the start of September looks like this:

➡️ $ACWI
$WSML (+0,03%) (150 €): As always, the foundation is being consistently strengthened.

➡️ $MELI (-0,51%) (€150) & Datadog (€75): Here I continue to build on my core conviction positions.

➡️ $TEM (+1,5%) (125 €): This is my tactical pick for the month. I am opening a position in a highly potent and diversifying bet on the AI medical revolution.

➡️ $DDOG (+2,57%) (75 €): A core position in my cl infrastructure cluster. Digital transformation and the need for cloud monitoring and security are unwavering megatrends for me.

➡️ $NOVO B (-2,31%) (3 €): This is not an active allocation, but the automatic reinvestment of dividends received to maximize the compound interest effect for this quality position.

4. tops & flops: A reflection of the rotation 📉📈

Top mover: 🟢

The list was topped this month by the spectacular performance of $IREN (-0,67%) (+60.69%), which is benefiting from the continuing demand for energy for AI data centers. My speculative bet on American Lithium (+20.00%) also showed strength. The recovery in $BABA (+2,84%) (+10.21%) following good news on the cloud division and AI chip development.

Flop mover: 🔴

As expected, my tech stocks were hit here. $CRWD (+0,69%) (-11.16%) and $DDOG (+2,57%) (-5.45%) suffered and the weak market environment for growth stocks, although the quarterly figures were fundamentally good. Also $1211 (-0,26%) (-8.22%) also suffered after disappointing figures; the situation here remains tense.

Conclusion:

August was perfect proof of why broad diversification across different sectors and themes is so crucial. Weakness in one area (US tech) was more than compensated for by strength in others (energy, China recovery). My flexible approach to monthly purchases allows me to react specifically to such market phases.

How did your August❓ go?

Which shares did you buy tactically ❓

I look forward to the exchange in the comments!

21 Comentários

Epi@Epi

You talk a lot about the advantage of diversification. I basically agree with you on that. And your portfolio in August too.

However, I'm surprised that, despite your speech, you don't diversify either in terms of asset classes or strategies. Why not? 🤔

•

Ver todas as 10 restantes respostas

Jarod@TradingHase

I see many parallels with my portfolio. My performance in August was just under 4%. However, this was due to the fresh purchases of some rockets such as Ondas and Iren. 😁

•

Tenbagger2024@Tenbagger2024

Thanks for the great detailed interim report

•

Chris@Multibagger

After 2 somewhat weaker months, things looked very good for me in August with a good +7%.
With 3 shares $IREN, $NBIS and $PPTA, 3 long-term investments broke through the 100% mark. I also sold 2 derivatives, $IREN and $GOOGL, at around 100% after a short holding period. Unfortunately, not much has happened yet in terms of book losses. This will probably happen in the last quarter at the earliest.

•

Der Spekulant@Derspekulant1

@Multibagger $NBIS I also find it super interesting, but for me the choice has fallen on $TEM for now. Thanks for your report!

•

Chris@Multibagger

@Derspekulant1 $TEM I have also added, but as a derivative with relatively low leverage and no maturity date, i.e. as a KO, but with a large gap.

•

Jarod@TradingHase

@Multibagger I'll probably have to add something to my watchlist. 😉 Unfortunately, I haven't dared to try leveraged products yet due to a lack of insight and will probably have to start looking for a simple explanation of the topic. Maybe you have a tip for reading?

•

TheMaverick@TheMaverick

I have seen lots of USA congress member buying Tempus AI.
However I don’t trust the founder history and track record.
He is also the founder of “Groupon” and that company is a disaster.
I am worried Tempus AI can be a Groupon 2.0

••

Der Spekulant@Derspekulant1

@TheMaverick but the metrics are Great and Future of Tempus ai is really good because they have a big Position in their market and its Some other AI Play With Not much competition. If this is Not the Future of healthcare with Big Data what Else ?

••

TheMaverick@TheMaverick

@Derspekulant1 well there are several competitors in the sector like ConcertAI, Flatiron Health, IQVIA, PathAI, Prognos Health, Resolution Bio (owned by Agilent) and the list goes on and on.
Tempus AI right now is one of the biggest player but is unprofitable (-24% operating margin) even if the overall situation is improving YoY.

At the end of the day what matters is the ability of the Management to perform well and since the CEO has already had a bad track record with Groupon and all the scandals which sorrounded the company like questionable accounting practice, failed financial projections etc...

Basically I don’t trust the CEO even if the sector in which the company operates is interesting

••

Der Spekulant@Derspekulant1

@TheMaverick
You're absolutely right about the CEO's track record with Groupon – it's a valid concern and a key part of the bear thesis. The key difference here is the business model. Groupon was a low-moat business dependent on marketing spend, whereas Tempus's core asset is its proprietary, multi-modal data library, which is incredibly difficult to replicate and grows more valuable over time. This creates a network effect that Groupon never had.

Regarding competition, you've listed some strong players. However, they often operate in slightly different niches:

Flatiron (now owned by Roche) is more focused on structuring EHR data for oncology clinics.

PathAI specializes in AI-powered Pathologe (analyzing tissue samples).

ConcertAI and IQVIA are also strong in real-world data but often focus on different data modalities or have a broader (less deep) scope.

Tempus's key differentiator is its focus on integrating genomic data at scale with clinical data, creating a unique, multi-modal dataset that is purpose-built for developing next-generation precision medicine.

The unprofitability is the central risk, as you noted. But the trend is highly positive: Adj. EBITDA loss improved from -$21.8M in Q4 2024 to just -$5.6M in Q2 2025 while revenue grew +625% YoY. This indicates massive operating leverage and a clear path to profitability, which the market is starting to recognize.

Ultimately, it's a bet on whether Tempus's superior, data-centric business model can overcome the valid concerns about its management's past. For me, the quality of the asset outweighs the history of the jockey. Appreciate the great discussion!

••